Samuel Zhang

Samuel Zhang, PhD, MBA, is an accomplished executive in the biotech and pharmaceutical industries, currently serving as Chief Business Officer at Innovent Biologics since April 2024, where responsibility includes leading global strategy and business development for a significant biotech firm. Prior to this role, Samuel was Chief Business Officer at Gracell Biotechnologies, facilitating a successful $1.2 billion sale to AstraZeneca. Additional experience includes strategic roles at NeoImmuneTech, Merus N.V., Novartis, and Bristol-Myers Squibb, focusing on immuno-oncology and product strategy, as well as significant contributions to clinical development and commercial success across various organizations. Educational credentials include an MBA from The Wharton School, a PhD in Molecular Biology from Columbia University, and a BS in Biological Sciences from Peking University.